
Supplementary figure



Supplementary figure. Additional blood immune modulations observed 1 month after Y⁹⁰TARE in HCC patients, as detected by multiparametric flow cytometry. (A) Treatment-induced increase in the percentage of CD3+CD8+, activated/exhausted CD3+LAG3+ lymphocytes and regulatory T cells (Treg, CD4+CD25hiFoxp3+), peaking one month after therapy; (B) Treatment-induced increase in PBMC of intermediate (CD14++CD16+) and non-classical (CD14+CD16++) monocytes and of activated CD14+ and HLA-DR+CD14+PD-L1+ monocytes, all peaking one month after treatment; (C) Treatment-induced increase of CD4+ and CD8+ T cells expressing the proliferative marker Ki67 in post-Y⁹⁰TARE (1 month) *vs* pre-Y⁹⁰TARE (time 0) PBMC; (D) IFN-y intracellular staining in post-Y⁹⁰TARE (1 month) *vs* pre-Y⁹⁰TARE (time 0) CD8+Ki67+ cells (p>0.05); (E) Increased frequency in post-Y⁹⁰TARE (1 month) compared to pre-Y⁹⁰TARE (time 0) of Ki67+CD4+ and Ki67+CD8+ T cells expressing a terminally differentiated effector (CCR7-CD45RA+) phenotype; decrease in both memory (central, CCR7+CD45RA-) and effector (CCR7-CD45RA-) subsets. For statistical analyses the Friedman (A, B) and Wilcoxon (C-E) tests were applied. Statistical significance was set at p<0.05.